Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $22.68 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

kalbe farma pt-unspons adr (PTKFY) Snapshot

Open
$22.68
Previous Close
$22.68
Day High
$22.68
Day Low
$22.68
52 Week High
12/3/14 - $30.18
52 Week Low
08/25/15 - $20.49
Market Cap
5.3B
Average Volume 10 Days
995.7
EPS TTM
--
Shares Outstanding
234.4M
EX-Date
05/28/15
P/E TM
--
Dividend
$0.28
Dividend Yield
1.24%
Current Stock Chart for KALBE FARMA PT-UNSPONS ADR (PTKFY)

Related News

No related news articles were found.

kalbe farma pt-unspons adr (PTKFY) Related Businessweek News

No Related Businessweek News Found

kalbe farma pt-unspons adr (PTKFY) Details

PT. Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs, energy drinks, ready-to-drink healthy beverage products, supplements, and other preventive products; nutritional products comprising powdered milk products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs; and non-milk nutritional products. In addition, the company operates a retail health service, Mitrasana Clinics, an integrated clinic network consisting of physician’s general practice, pharmacies, laboratory, and health mart, which also offers hemodialysis services; contract services and resources, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; produces reagents; operates as an agent for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; markets and distributes ophthalmic products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. PT. Kalbe Farma Tbk. was founded in 1966 and is headquartered in Jakarta, Indonesia.

12,616 Employees
Last Reported Date: 07/31/15
Founded in 1966

kalbe farma pt-unspons adr (PTKFY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kalbe farma pt-unspons adr (PTKFY) Key Developments

PT Kalbe Farma Tbk Announces Earnings Results for the First Half of 2015; Provides Earnings Guidance for 2015; Provides Dividend Guidance for 2015

PT Kalbe Farma Tbk announced earnings results for the first semester of 2015. Net sales grew by 4.1% to reach IDR 8,720 billion from IDR 8,380 billion in the same period in 2014. This was mostly due to slowing demand in general, impact of product recall, and discontinued distributorship agreement with a third party principal since end of 2014. Gross profit was up 7.1% to IDR 4,298 billion. Operating income grew by 3.6% compared to the same period last year, with a ratio of 15.8% of net sales. The company is committed to maintain its operating profit growth by improving its marketing and sales effectiveness and monitoring the other operating expenses. Net profit increased by 7.1% to reach IDR 1,063 billion from IDR 993 billion in first half of 2014. Higher net profit growth was mostly attributable to improvement in financing expense and other operating income. On account of the fragile and unstable macro condition and market competition, the company revised net sales growth outlook for 2015 to 5%-7% and net earnings growth outlook to 6%-8%. Operating profit margin remains unchanged at the level of 16%-17%. A capital expenditure budget of IDR 0.9 trillion to IDR 1.1 trillion has been set for both production and distribution capacity expansion. The company's dividend policy remains at the level of around 40%-50%, depending on cash availability and internal fund requirement. For fiscal year 2014, the company have distributed dividend equivalent to a 43% payout ratio which has been paid on June 17, 2015.

PT. Kalbe Farma Tbk. to Report Q2, 2015 Results on Jul 31, 2015

PT. Kalbe Farma Tbk. announced that they will report Q2, 2015 results on Jul 31, 2015

Kalbe Farma Revised Sales Guidance for the Year 2015

Kalbe Farma (Indonesia) revised sales outlook for the year 2015. For the period, the company cut its sales growth target to 7% from 11% year on year. The company also adjusted its annual revenue target to IDR 19 trillion (USD 1.42 billion). Initially the company expects full-year net sales growth of 11% to 13%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTKFY:US $22.68 USD 0.00

PTKFY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTKFY.
View Industry Companies
 

Industry Analysis

PTKFY

Industry Average

Valuation PTKFY Industry Range
Price/Earnings 35.0x
Price/Sales 4.2x
Price/Book 7.8x
Price/Cash Flow 35.0x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALBE FARMA PT-UNSPONS ADR, please visit www.kalbe.co.id. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.